Overview

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborator:
Cytogen Corporation
Treatments:
Androgens
Ascorbic Acid
Bicalutamide
Estrogens, Conjugated (USP)
Ethylene
Goserelin
Methyltestosterone
Samarium ethylenediaminetetramethylenephosphonate
Samarium Sm-153 lexidronam